Key Takeaways Sarepta Therapeutics shares sank to their lowest level in nine years Monday after a second patient taking its ...

Sarepta Therapeutics Inc. plummeted in early trading after reporting a second patient died of acute liver failure while being ...

Supernus Pharmaceuticals said it is acquiring Sage Therapeutics, the distressed maker of a drug for postpartum depression, ...

Another person treated with Elevidys suffered acute liver failure, leading Sarepta to discontinue treatment in certain patients while it evaluates new safety precautions.

Cambridge-based Sarepta Therapeutics said it was halting shipments of its Duchenne muscular dystrophy gene therapy for ...

BMO Capital and Piper Sandler downgraded Sarepta Therapeutics (NASDAQ:SRPT) after the company reported a second death linked to its gene therapy Elevidys in a non-ambulatory Duchenne muscular ...

Investing.com -- BMO Capital and Piper Sandler downgraded Sarepta Therapeutics (NASDAQ: SRPT) after the company reported a second death linked to its gene therapy Elevidys in a non-ambulatory Duchenne ...

Sarepta Therapeutics ( NASDAQ: SRPT) fell ~38% in the premarket on Monday after the company reported a second fatality from ...

U.S. stock futures point higher, Victoria's Secret shares rise on a report that an activist investor is building a stake in the lingerie company, and EchoStar stock jumps on a report that President ...

Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.